Diurnal variability of C-reactive protein in obstructive sleep apnea

Department of Psychiatry, University of California, San Diego, La Jolla, 92093-0804, USA.
Sleep And Breathing (Impact Factor: 2.48). 06/2009; 13(4):415-20. DOI: 10.1007/s11325-009-0268-0
Source: PubMed


The objective of this study is to examine the diurnal variability of C-reactive protein (CRP) in obstructive sleep apnea (OSA).
Participants included 44 women and men with untreated OSA (mean apnea/hypopnea index = 37.5, SD +/- 28) and 23 healthy adults with no OSA. Sleep was monitored with polysomnography in the University of California San Diego General Clinical Research Center. Over a 24-h period, blood was collected every 2 h, and CRP levels were determined.
Adjusting for age, gender, and body mass index, a significant group by time interaction showed that patients with OSA had higher CRP levels during the daytime (8:00 a.m.-8:00 p.m.) versus the nighttime (10:00 p.m. until 6:00 p.m.; p < 0.001). Non-apneics showed no significant change in CRP levels during the 24 h.
The findings indicate that sleep apnea patients have disproportionately elevated CRP levels in the day versus the nighttime, possibly as a result of carryover effects of nighttime arousal into the daytime.

Download full-text


Available from: Sonia Ancoli-Israel, Oct 08, 2015
1 Follower
21 Reads
  • Source
    • "The stressor combines two commonly used speech tasks (the 'Saab speech task' (Saab et al., 1989) and 'describing best and worst personal characteristics' (van Eck et al., 1996), as described by Bosch et al. (2003). The tasks have been validated in a large number of studies, and induce a robust physiological activation (catecholamine , HPA, immune) and negative mood increases (Bosch et al., 2007, 2009; Mills et al., 2009; Redwine et al., 2004). To enhance social stress, the speeches were attended by a small audience (consisting of a female nurse, a female research assistant, and a male psychologist) and videotaped (allegedly to have the quality of the performance rated) (Bosch et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Macrophage Migration Inhibitory Factor (MIF) is a proinflammatory cytokine produced by leukocytes and the secretory cells of the HPA axis. Remarkably, glucocorticoids (GC) induce leukocyte MIF secretion, while MIF renders leukocytes insensitive to the anti-inflammatory effects of glucocorticoids. In light of reported associations between dysphoric states, increased inflammatory activity, and reduced GC sensitivity, the current study investigated the association between MIF, loneliness and depressive symptoms. The study further investigated the relation between plasma MIF and markers of HPA function, i.e., diurnal cortisol and the cortisol response to acute stress. Healthy university undergraduates (N=126; 64 women) were invited to participate if their scores on the Beck Depression Inventory or UCLA loneliness scale were in the upper or lower quintile of their peer group. Plasma MIF and salivary cortisol were measured in response to a public speaking task. Ambulatory diurnal cortisol was assessed for 5 consecutive days. MIF levels were 40% higher in the high-depressive symptoms group compared to the low depressive symptoms group. Elevated MIF was also associated with a smaller cortisol response to acute stress and lower diurnal morning cortisol values. The observed association between HPA function and MIF remained robust after adjustment for depressive symptoms, and demographic, anthropomorphic, and behavioural factors. High levels of depressive symptoms were likewise associated with lower morning cortisol, but this association became non-significant after adjustment for MIF. MIF may be an important neuro-immune mediator linking depressive symptoms with inflammation and HPA dysregulation.
    Brain Behavior and Immunity 04/2010; 24(7):1202-8. DOI:10.1016/j.bbi.2010.03.011 · 5.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: During the first 6 months of the year 2009 have been published numerous articles about sleep apnea-hypoapnea syndrome (SAHS). These articles reaffirm different aspects published previously and gives new light on other areas less explored. Thus, these publications reinforce the evidence that SAHS is associated with increased inflammatory mechanisms and that CPAP therapy decrease inflammatory mechanisms. Also, these articles strengthens the association between this patology and morbidity-mortality, especially cardio-cerebrovascular disease. The dimension that reaches sleep apnea does necessary to achieve an appropriate population screening, a correct treatment and close follow-up, in order to obtain better control of these patients and fewer complications.
    01/2010; 13(1):23–28. DOI:10.1016/S1576-9895(10)70030-8
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of overweight and obesity in the United States remains high. Commercial weight loss programs may contribute to efforts to reduce the prevalence of overweight and obesity, although few studies have examined their efficacy in controlled trials. To test whether a free prepared meal and incentivized structured weight loss program promotes greater weight loss and weight loss maintenance at 2 years compared with usual care. A randomized controlled trial of weight loss and weight loss maintenance in 442 overweight or obese women (body mass index, 25-40) aged 18 to 69 years (mean age, 44 years) conducted at US institutions over 2 years with follow-up between November 2007 and April 2010. The program, which involves in-person center-based or telephone-based one-to-one weight loss counseling, was available over a 2-year period. Behavioral goals were an energy-reduced, nutritionally adequate diet, facilitated by the inclusion of prepackaged food items in a planned menu during the initial weight loss phase, and increased physical activity. Participants assigned to usual care received 2 individualized weight loss counseling sessions with a dietetics professional and monthly contacts. Weight loss and weight loss maintenance. Weight data were available at 24 months for 407 women (92.1% of the study sample). In an intent-to-treat analysis with baseline value substitution, mean weight loss was 7.4 kg (95% confidence interval [CI], 6.1-8.7 kg) or 7.9% (95% CI, 6.5%-9.3%) of initial weight at 24 months for the center-based group, 6.2 kg (95% CI, 4.9-7.6 kg) or 6.8% (95% CI, 5.2%-8.4%) for the telephone-based group, and 2.0 kg (95% CI, 0.6-3.3 kg) or 2.1% (95% CI, 0.7%-3.5%) for the usual care control group after 24 months (P < .001 for intervention effect). Compared with usual care, this structured weight loss program resulted in greater weight loss over 2 years. Identifier: NCT00640900.
    JAMA The Journal of the American Medical Association 10/2010; 304(16):1803-10. DOI:10.1001/jama.2010.1503 · 35.29 Impact Factor
Show more